Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cantox renames Pharmaceutical & Healthcare Division
Lindsay Donald, vice president of Ashuren Pharmaceutical & Healthcare, said: “The decision to rename the Pharmaceutical & Healthcare Division as ‘Ashuren Health Sciences’ was taken in order to
Lindsay Donald, vice president of Ashuren Pharmaceutical & Healthcare, said: “The decision to rename the Pharmaceutical & Healthcare Division as ‘Ashuren Health Sciences’ was taken in order to
As part of the collaboration, Celltrion will provide process development expertise and supply clinical and commercial material to support the clinical development program for CSL 360 and commercialization
New study results show that Menveo was well-tolerated and generated high levels of immunogenicity in infants against meningococcal serogroups A, C, W-135 and Y with a standard infant
In the studies reported, SF1126 showed favorable pharmacokinetics and pharmacodynamic effects as indicated by inhibition of downstream signaling elements both in vitro and in vivo. In addition, SF1126
The Safety Monitoring Committee (SMC) reviewed the safety data from the first group of patients that have completed 70 days in the study. On the basis of the
The OB-202 study is a 28 week, randomized, double blind, placebo controlled, efficacy and safety study of Qnexa in the glycemic management of obese type 2 diabetics. The
The Phase IIa trial will be a randomized, double-blind, placebo-controlled study. The trial will enroll 96 patients with age associated memory impairment (AAMI) who will be randomized to
BioAlliance Pharma said that the grant of the marketing authorization in the UK represents an important milestone for the company especially with the payment of E2.5 million by
On December 26, 2007, the company entered into a securities purchase agreement in connection with a private placement to a group of institutional accredited investors. In the closings,
Under the terms of the settlement, Illumina agreed, without admitting liability, to make a one-time payment to Affymetrix of $90 million. Affymetrix agreed to dismiss with prejudice all